Improvement of plant quality on Potted Saxifraga rosacea with Plant Growth Retardants

학위논문 (석사)-- 서울대학교 대학원 : 원예학과, 2011.8. 김기선.Maste

사이클로스포린-리피드 공유결합체를 이용한 사이클로스포린 주사제의 개발

학위논문(석사)--서울대학교 대학원 :약학과 물리약학전공,2000.Maste

충남기후정보브리핑 27호-서해안 지역 기상·기후 정보현황

- 기후변화로 인한 이상기상·기후 발생빈도 급증, 이에 따른 피해 증가와 국지적 극한기후 발생빈도 증가로 지역 맞춤형 기상·기후 대응체계 구축 필요성이 증대됨 서해연안 해수온도 상승, 중국내륙 북서풍에 의한 기상·기후 영향 모니터링과 예측분석을 위한 서해안 기상·기후 전진기지를 제안함1. 서해안 지역 기상·기후 정보현황 2. 서해안미래청정대기센터 설립 필요성 3. 서해안미래청정대기센터의 기

Estimations and Long-term Trend of Sea-to-air Dimethyl Sulfide (DMS) Flux using Satellite Observation Data

The long-term linear trend of global sea-to-air dimethyl sulfide (DMS) flux was analyzed over a 16-year time span (2000~2015), based on satellite observation data. The emission rates of DMS (i.e. DMS flux) in the global ocean were estimated from sea surface DMS concentrations, which were constructed with chlorophyll a (Chl-a) concentrations and mixed layer depths (MLD), and transfer velocity from sea to air, which was parameterized with sea surface wind (SSW) and sea surface temperature (SST). In general, the DMS flux in the global ocean exhibited a gradual decreasing pattern from 2000 (a total of 12.1 Tg/yr) to 2015 (10.7 Tg/yr). For the latitude band (10o interval between 0o and 60o), the DMS flux at the low latitude of the Northern (NH) and Southern hemisphere (SH) was significantly higher than that at the middle latitude. The seasonal mean DMS flux was highest in winter followed by in summer in both hemispheres. From the longterm analysis with the Mann-Kendall (MK) statistical test, a clear downward trend of DMS flux was predicted to be broad over the global ocean during the study period (NH: −0.001~−0.036 μmol/m2/day per year, SH: −0.011~−0.051 μmol/m2/day per year). These trend values were statistically significant (p < 0.05) for most of the latitude bands. The magnitude of the downward trend of DMS flux at the low latitude in the NH was somewhat higher than that at the middle latitude during most seasons, and vice versa for the SH. The spatio-temporal characteristics of DMS flux and its long-term trend were likely to be primarily affected not only by the SSW (high positive correlation of r = 0.687) but also in part by the SST (r = 0.685).33scopuskc

Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)

Purpose YoungPEARL (KCSG-BR15-10) trial demonstrated a significant progression-free survival (PFS) benefit for premenopausal patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) for palbociclib plus exemestane with ovarian function suppression compared to capecitabine. However, the number of tamoxifen-sensitive premenopausal patients was small because most recurrences occurred early during adjuvant endocrine therapy (ET), with tamoxifen being the only drug used; hence, the data for these patients were limited. Here we present a subgroup analysis according to tamoxifen sensitivity from the YoungPEARL study. Materials and Methods Patients were randomized 1:1 to receive palbociclib+ET (oral exemestane 25 mg/day for 28 days, palbociclib 125 mg/day for 21 days, plus leuprolide 3.75 mg subcutaneously every 4 weeks) or chemotherapy (oral capecitabine 1,250 mg/m(2) twice daily for 14 days every 3 weeks). Tamoxifen resistance was defined as: relapse while on adjuvant tamoxifen, relapse within 12 months of completing adjuvant tamoxifen, or progression while on first-line tamoxifen within 6 months for MBC. Results In total, 184 patients were randomized and 178 were included in the modified intention-to-treat population. PFS improvement in the palbociclib+ET group was observed in tamoxifen-sensitive patients (hazard ratio, 0.38; 95% confidence interval, 0.12 to 1.19). Furthermore, palbociclib+ET prolonged median PFS compared with capecitabine in tamoxifen-sensitive (20.5 months vs. 12.6 months) and tamoxifen-resistant (20.1 months vs. 14.5 months) patients. Palbociclib+ET demonstrated a higher rate of objective response, disease control, and clinical benefit in tamoxifen-sensitive patients. Conclusion This post hoc exploratory analysis suggests that palbociclib+ET is a promising therapeutic option for premenopausal HR+/HER2- MBC patients irrespective of tamoxifen sensitivity